<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03174977</url>
  </required_header>
  <id_info>
    <org_study_id>15-17586</org_study_id>
    <nct_id>NCT03174977</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Distribution of Raltegravir by PET/MR</brief_title>
  <official_title>Pharmacokinetics Distribution of Raltegravir Using Radiolabeling in HIV-infected Patients by PET/MR: a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center drug distribution and pharmacokinetic study of a single microdose of
      18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a
      raltegravir-containing ART regimen. After administration of IV 18F-raltegravir, subjects will
      undergo PET/MRI in order to determine the distribution of radiolabeled drug through the
      lymphoreticular system and other tissues throughout the entire body.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with microdose (&lt;2.5 millicurie; mCi) 18F-Raltegravir-related adverse events as measured by clinical observation during single intravenous dose administration and PET/MR imaging</measure>
    <time_frame>One imaging session within 1 to 6 hours following administration of 18F-Raltegravir</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole-body distribution (coronal through pelvis) of radiolabeled 18F-Raltegravir as determined by PET-MR scanning and quantification of radiographic regions of interest (ROI) immediately following and up to 4 hours after drug administration.</measure>
    <time_frame>One imaging session within 1 to 6 hours following administration of 18F-Raltegravir</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>18F-Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-Raltegravir</intervention_name>
    <description>A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.</description>
    <arm_group_label>18F-Raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years

          -  HIV infection

          -  Initiated a combination ART (HAART) regimen

        Exclusion Criteria:

          -  Screening absolute neutrophil count &lt;1,000 cells/mm3, platelet count &lt;70,000
             cells/mm3, hemoglobin &lt; 8 mg/dL, estimated creatinine clearance &lt;40 mL/minute,
             aspartate aminotransferase &gt;100 units/L, alanine aminotransferase &gt;100 units/L.

          -  Serious illness requiring hospitalization or parental antibiotics within the preceding
             3 months.

          -  Any vaccination 2 weeks prior to baseline (Day 0) visit and throughout the study
             period.

          -  Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory
             drug in the preceding 16 weeks (e.g. corticosteroid therapy equal to or exceeding a
             dose of 15 mg/day of prednisone for more than 10 days, IL-2, interferon-alpha,
             methotrexate, cancer chemotherapy). NOTE: Use of inhaled or nasal steroid use is not
             exclusionary.

          -  Pregnant or breastfeeding women. Females of childbearing potential must have a
             negative serum pregnancy test at screening and agree to use a double-barrier method of
             contraception throughout the study period.

          -  Have a cardiac pacemaker or other indwelling foreign object that are contraindicated
             for MR imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy J Henrich, MD</last_name>
    <phone>415-206-5518</phone>
    <email>timothy.henrich@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy J Henrich, MD</last_name>
      <phone>415-206-5518</phone>
      <email>timothy.henrich@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy J Henrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry F Vanbrocklin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven J Deeks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benajamin Franc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Aweeka, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Timothy Henrich</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

